Cabaletta Bio (CABA) Income towards Parent Company (2018 - 2025)
Cabaletta Bio (CABA) recorded quarterly Income towards Parent Company of -$41.8 million in Q4 2025, up 7.77% quarter-over-quarter from -$45.4 million in Q3 2025, and down 28.4% on a YoY basis from -$58.4 million in Q4 2024.
Cabaletta Bio (CABA) Income towards Parent Company (2018 - 2025) Analysis & Trends
Cabaletta Bio's Income towards Parent Company history runs 8 years deep, the most recent figure standing at -$41.8 million for Q4 2025.
- In Q4 2025, Income towards Parent Company fell 28.4% year-over-year to -$41.8 million; the TTM figure through Dec 2025 stood at -$168.2 million (down 45.18% YoY), while the FY2025 annual figure was -$168.2 million, down 45.18% from the prior year.
- Income towards Parent Company was -$41.8 million for Q4 2025 at Cabaletta Bio, up from -$45.4 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of -$9.7 million in Q1 2021 to a low of -$45.4 million in Q3 2025.
- Historically, Income towards Parent Company has averaged -$22.6 million across 5 years, with a median of -$16.2 million in 2023.
- The sharpest annual moves came in 2022 and 2024: Income towards Parent Company climbed 1.15% in 2022, then tumbled 90.53% in 2024.
- A 5-year view of Income towards Parent Company shows it stood at -$13.9 million in 2021, then fell by 12.99% to -$15.7 million in 2022, then tumbled by 33.1% to -$20.9 million in 2023, then tumbled by 56.02% to -$32.6 million in 2024, then fell by 28.4% to -$41.8 million in 2025.
- The last three Income towards Parent Company figures came in at -$41.8 million (Q4 2025), -$45.4 million (Q3 2025), and -$45.1 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Cabaletta Bio | 151.84 Mn | 18.24 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -41.84 Mn |
| Sep 30, 2025 | -45.36 Mn |
| Jun 30, 2025 | -45.07 Mn |
| Mar 31, 2025 | -35.94 Mn |
| Dec 31, 2024 | -32.59 Mn |
| Sep 30, 2024 | -30.63 Mn |
| Jun 30, 2024 | -27.60 Mn |
| Mar 31, 2024 | -25.05 Mn |
| Dec 31, 2023 | -20.89 Mn |
| Sep 30, 2023 | -16.45 Mn |
| Jun 30, 2023 | -14.49 Mn |
| Mar 31, 2023 | -15.85 Mn |
| Dec 31, 2022 | -15.69 Mn |
| Sep 30, 2022 | -11.43 Mn |
| Jun 30, 2022 | -12.91 Mn |
| Mar 31, 2022 | -12.95 Mn |
| Dec 31, 2021 | -13.89 Mn |
| Sep 30, 2021 | -11.56 Mn |
| Jun 30, 2021 | -11.14 Mn |
| Mar 31, 2021 | -9.70 Mn |